WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Nicole Zeinstra
Associate
Patents and Innovations
Boulder
nzeinstra@wsgr.com

D650-461-7386

Download vCard
Open PDF

Dr. Nicole Zeinstra is an associate at Wilson Sonsini Goodrich & Rosati, where her work focuses on patents and innovations. Her background includes cell therapy, stem cell biology, tissue engineering, molecular biology, protein engineering, and immunology.

Prior to joining the firm, Nicole earned her Ph.D. in bioengineering from the University of Washington in the labs of Professors Charles Murry and Ying Zheng. Her research focused on engineering thick vascularized patches for cardiac repair. During graduate school, she was also a venture analyst at Washington Research Foundation & WRF Capital, where she assessed scientific and market potential of life sciences innovations.

Experience

Dr. Nicole Zeinstra is an associate at Wilson Sonsini Goodrich & Rosati, where her work focuses on patents and innovations. Her background includes cell therapy, stem cell biology, tissue engineering, molecular biology, protein engineering, and immunology.

Prior to joining the firm, Nicole earned her Ph.D. in bioengineering from the University of Washington in the labs of Professors Charles Murry and Ying Zheng. Her research focused on engineering thick vascularized patches for cardiac repair. During graduate school, she was also a venture analyst at Washington Research Foundation & WRF Capital, where she assessed scientific and market potential of life sciences innovations.

Education
  • J.D., UC Berkeley School of Law, 2025
  • Ph.D., Bioengineering, University of Washington

    NIH Ruth L. Kirschstein National Research Service Award Individual Predoctoral Fellowship (F31), UW Bioengineering Cardiovascular Training Grant, UW Institute for Stem Cell and Regenerative Medicine Fellow

  • B.S., Double Major in Chemical-Biological Engineering and Biology, Massachusetts Institute of Technology, 2016

    MIT Bioengineering Research and Innovation Scholar, NCAA Postgraduate Scholar in Track and Field, CoSIDA Academic All-American in Cross Country/Track and Field

Admissions
  • State Bar of Colorado
  • U.S. Patent and Trademark Office
Credentials
Education
  • J.D., UC Berkeley School of Law, 2025
  • Ph.D., Bioengineering, University of Washington

    NIH Ruth L. Kirschstein National Research Service Award Individual Predoctoral Fellowship (F31), UW Bioengineering Cardiovascular Training Grant, UW Institute for Stem Cell and Regenerative Medicine Fellow

  • B.S., Double Major in Chemical-Biological Engineering and Biology, Massachusetts Institute of Technology, 2016

    MIT Bioengineering Research and Innovation Scholar, NCAA Postgraduate Scholar in Track and Field, CoSIDA Academic All-American in Cross Country/Track and Field

Admissions
  • State Bar of Colorado
  • U.S. Patent and Trademark Office

Select Publications

  • Lead author with A. L. Frey, Z. Xie, L. P. Blakely, R. K. Wang, C. E. Murry, and Y. Zheng, “Stacking thick perfusable human microvascular grafts enables dense vascularity and rapid integration into infarcted rat hearts,” 301 Biomaterials 122250, 2023
  • Lead author with M.A. Redd, W. Qin, W. Wei, A. Martinson, Y. Wang, Y. Zheng, et al., “Patterned human microvascular grafts enable rapid vascularization and increase perfusion in infarcted rat hearts,” 10(1) Nature Communications 584, 2019
  • Co-author with Z. Xie,  M. A. Kirby, N. M. Le, C. E. Murry, Y. Zheng, and R. K. Wang, "Quantifying microvascular structure in healthy and infarcted rat hearts using optical coherence tomography angiography," 43(8) IEEE Transactions on Medical Imaging 2878-2887, 2024
  • Co-author with P. Tang, M.A. Kirby, N. Le, Y. Li, G.N. Lu, R.K. Wang, et al., “Polarization sensitive optical coherence tomography with single input for imaging depth-resolved collagen organizations,” 10(1) Light: Science & Applications 237, 2021
Insights

Select Publications

  • Lead author with A. L. Frey, Z. Xie, L. P. Blakely, R. K. Wang, C. E. Murry, and Y. Zheng, “Stacking thick perfusable human microvascular grafts enables dense vascularity and rapid integration into infarcted rat hearts,” 301 Biomaterials 122250, 2023
  • Lead author with M.A. Redd, W. Qin, W. Wei, A. Martinson, Y. Wang, Y. Zheng, et al., “Patterned human microvascular grafts enable rapid vascularization and increase perfusion in infarcted rat hearts,” 10(1) Nature Communications 584, 2019
  • Co-author with Z. Xie,  M. A. Kirby, N. M. Le, C. E. Murry, Y. Zheng, and R. K. Wang, "Quantifying microvascular structure in healthy and infarcted rat hearts using optical coherence tomography angiography," 43(8) IEEE Transactions on Medical Imaging 2878-2887, 2024
  • Co-author with P. Tang, M.A. Kirby, N. Le, Y. Li, G.N. Lu, R.K. Wang, et al., “Polarization sensitive optical coherence tomography with single input for imaging depth-resolved collagen organizations,” 10(1) Light: Science & Applications 237, 2021

Biological Sciences and Biotechnology

  • Cell biology
  • Cell therapy
  • Immunology
  • Molecular biology
  • Stem cell biology

Therapeutics and Drug Discovery

  • CRISPR
  • Gene editing

Diagnostics and Medical Devices

  • Medical imaging

Chemistry and Material Science

  • Protein engineering

Engineering and Technology

  • 3D bioprinting
  • Microfluidics

Genomics and Data Analysis

  • Single-cell sequencing

Miscellaneous

  • Fluorescence microscopy
Technical Fluency

Biological Sciences and Biotechnology

  • Cell biology
  • Cell therapy
  • Immunology
  • Molecular biology
  • Stem cell biology

Therapeutics and Drug Discovery

  • CRISPR
  • Gene editing

Diagnostics and Medical Devices

  • Medical imaging

Chemistry and Material Science

  • Protein engineering

Engineering and Technology

  • 3D bioprinting
  • Microfluidics

Genomics and Data Analysis

  • Single-cell sequencing

Miscellaneous

  • Fluorescence microscopy
Focus Areas
  • Patents and Innovations
Recent Insights
Client Highlights
Firm Advises Arcellx on $7.8 Billion Acquisition by Gilead
On February 23, 2026, Gilead Sciences announced that it has entered into a definitive agreement to acquire Arcellx, a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases, for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises OneSkin on IP Matters Related to Series A
On November 13, 2024, OneSkin, a biotech skin health brand, announced the successful completion of an oversubscribed Series A financing led by Selva Ventures, with participation from PLUS Capital, Unilever Ventures, Able Partners, and former investors SOSV, Meta Planet, and additional investors. The latest round brings the total company funding to $20 million. Wilson Sonsini Goodrich & Rosati advised OneSkin on intellectual property matters related to the transaction and has advised the company on IP matters generally since its founding in 2016.
Learn More
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.